Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DWR6A9
|
|||
| Drug Name |
ML364
|
|||
| Synonyms |
1991986-30-1; 2-[(4-methylphenyl)sulfonylamino]-n-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide; NCGC00262995-02; CHEMBL3392741; SCHEMBL20782884; BCP20769; EX-A4472; ML-364; s6748; AKOS032944928; ZINC169341604; CS-6197; NCGC00262995-01; AS-55828; HY-100900; 2-((4-methylphenyl)sulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide; 2-(4-Methylphenylsulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Preclinical | [1] | |
| Company |
National Institutes of Health
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H18F3N3O3S2
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC(=C2)C(F)(F)F)C(=O)NC3=NC(=CS3)C4=CC=CC=C4
|
|||
| InChI |
1S/C24H18F3N3O3S2/c1-15-7-10-18(11-8-15)35(32,33)30-20-13-17(24(25,26)27)9-12-19(20)22(31)29-23-28-21(14-34-23)16-5-3-2-4-6-16/h2-14,30H,1H3,(H,28,29,31)
|
|||
| InChIKey |
QZUGMNXETPARLI-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ubiquitin carboxyl-terminal hydrolase 2 (USP2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78. | |||
| REF 2 | The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer. Cell Death Differ. 2020 Sep;27(9):2710-2725. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.